Adjuvant therapy for mucosal melanoma in the era of immune checkpoint inhibitors

Chin Clin Oncol. 2024 Feb;13(1):13. doi: 10.21037/cco-23-61. Epub 2023 Oct 9.

Authors

Yasuhiro Nakamura¹, Tatsuhiko Mori¹

Affiliation

¹ Department of Skin Oncology/Dermatology, Saitama Medical University International Medical Center, Saitama, Japan.

PMID: 37817508
DOI: 10.21037/cco-23-61

No abstract available

Keywords: Melanoma; immunotherapy; programmed cell death 1 receptor.

MeSH terms

Humans
Immune Checkpoint Inhibitors / pharmacology
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy
Melanoma*
Nivolumab / therapeutic use
Skin Neoplasms* / drug therapy

Substances

Immune Checkpoint Inhibitors
Nivolumab